CMPS — COMPASS Pathways Share Price
0.000.00%
Last trade - 00:00- $921.70m
- $730.26m
- 29
- 18
- 75
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.08 | ||
| Price to Tang. Book | 4.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.4% | ||
| Return on Equity | -58.21% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 24th, 2020
- Public Since
- September 18th, 2020
- No. of Shareholders
- 33
- No. of Employees
- 186
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 109,987,621
- Address
- 3Rd Floor, 1 Ashley Road, ALTRINCHAM, WA14 2DT
- Web
- https://compasspathways.com/
- Phone
- +44 16469053974
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for CMPS
Q1 2024 Compass Pathways PLC Earnings Release
Compass Pathways PLC Annual Shareholders Meeting
Q2 2024 Compass Pathways PLC Earnings Release
Similar to CMPS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the COMPASS Pathways share price?
As of Today at 19:05 UTC, shares in COMPASS Pathways are trading at $8.38. This share price information is delayed by 15 minutes.
How has the COMPASS Pathways share price performed this year?
Shares in COMPASS Pathways last closed at $8.38 and the price had moved by -11.7% over the past 365 days. In terms of relative price strength the COMPASS Pathways share price has underperformed the S&P500 Index by -26.52% over the past year.
What are the analyst and broker recommendations for COMPASS Pathways?
The overall consensus recommendation for COMPASS Pathways is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the COMPASS Pathways dividend yield?
COMPASS Pathways does not currently pay a dividend.
Does COMPASS Pathways pay a dividend?
COMPASS Pathways does not currently pay a dividend.
When does COMPASS Pathways next pay dividends?
COMPASS Pathways does not currently pay a dividend.
How do I buy COMPASS Pathways shares?
To buy shares in COMPASS Pathways you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of COMPASS Pathways?
As of the previous close price of $8.38, shares in COMPASS Pathways had a market capitalisation of $921.70m.
Where are COMPASS Pathways shares listed?
Here are the trading details for COMPASS Pathways:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CMPS
What kind of share is COMPASS Pathways?
Based on an overall assessment of its quality, value and momentum COMPASS Pathways is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a COMPASS Pathways share price forecast for 2024?
The analyst consensus target price for shares in COMPASS Pathways is $41.25. That is 392.24% above the last closing price of $8.38.
Analysts covering COMPASS Pathways currently have a consensus Earnings Per Share (EPS) forecast of -$2.29 for the next financial year.
What is the trend in the COMPASS Pathways share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like COMPASS Pathways. Over the past six months, its share price has outperformed the S&P500 Index by +22.87%.
As of the last closing price of $8.38, shares in COMPASS Pathways were trading -1.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the COMPASS Pathways PE Ratio?
The COMPASS Pathways PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of COMPASS Pathways?
We do not have data on COMPASS Pathways' directors